Clincial Practice Guidelines
DHS Analytical Studies No. 36
DHS ANALYTICAL STUDIES 62
Results from studies evaluating the effectiveness of focused psychosocial support interventions in children exposed to traumatic events in humanitarian settings in low-income and middle-income countries have been inconsistent, showing varying results by setting and subgroup (eg, age or gender). We a...imed to assess the effectiveness of these interventions, and to explore which children are likely to benefit most.
Lancet Glob Health 2018; 6: e390–400
more
Recognition, Assessment and Treatment
National Clinical Guideline Number 159
This casebook collects 64 case studies, each of which raises an important and difficult ethical issue connected with planning, reviewing, or conducting health-related research. The book’s purpose is to contribute to thoughtful analysis of these issues by researchers and members of research ethics ...committees (RECs, known in some places as ethical review committees or institutional review boards), particularly those involved with studies that are conducted or sponsored internationally.
more
WHO clinical guidelines.
For the first time, WHO has published guidelines to help (primarily) front-line healthcare providers give high-quality, compassionate, and respectful care to children and adolescents (up to age 18) who have or may have experienced sexual abuse, including sexual assault or r...ape.
more
DHS Analytical Studies No. 55.
DHS Analytical Studies No. 39
Clinical guideline | Published: 11 January 2012 | nice.org.uk/guidance/cg137
DHS Analytical Studies No. 44 Rockville, Maryland, USA: ICF International.
Rapid review and case studies from Member States
WHO clinical and policy guidelines
arrow country studies
Political developments in Myanmar/Burma prompted the Asian-Pacific Resource and Research Centre for Women (ARROW) in 2013 to undertake a small-scale scoping study to re-evaluate and refine its advocacy strategies for sexual and reproductive health and rights (SRHR), and to s...trengthen partnerships for advocacy with civil society organisations (CSO) working on SRHR in the country. The study aimed to identify the status of and the potential for SRHR advocacy by CSOs in Central Myanmar/Burma and in Eastern states along the Thai-Myanmar/Burma border, and increase the current knowledge base on SRHR issues, gaps, and challenges.
more
Настоящее руководство «Клиническое ведение случаев COVID-19» базируется на
вышеуказанных стратегических приоритетах и адресовано клиницистам, участвующим в
оказа...ии помощи пациентам с подозреваемой или подтвержденной инфекцией COVID-19.
Оно не предназначено для того, чтобы заменить индивидуальное клиническое суждение или
консультацию специалиста, но призвано помочь клиническим работникам в обеспечении
наиболее эффективного ведения случаев. Повышенное внимание в настоящем руководстве
уделяется вопросам, касающимся особых и уязвимых групп населения, таких как дети,
пожилые люди и беременные женщины.
Interim guidance on clinical management COVID-19
more
HTS Teologiese Studies/Theological StudiesISSN: (Online) 2072-8050, (Print) 0259-9422P
HTS Teologiese Studies/Theological Studies ISSN: (Online) 2072-8050, (Print) 0259-9422
MOH clinical practice guidelines
BMJ 2020; 370 doi: https://doi.org/10.1136/bmj.m3379
Rapid Recommendation and visual graph. This is the fifth version (update 4) of the living guideline (BMJ 2020;370:m3379). When citing this article, please consider adding the update number and date of access for clarity. The publication of the RE...COVERY and REMAP-CAP randomised controlled trials triggered this guideline update, resulting in a strong recommendation for interleukin-6 (IL-6) receptor blockers (tocilizumab or sarilumab) in patients with severe or critical covid-19.
Prior recommendations: (a) A recommendation not to use ivermectin in patients with covid-19, regardless of disease severity, except in the context of a clinical trial; (b) a strong recommendation against the use of hydroxychloroquine in patients with covid-19, regardless of disease severity; (c) a strong recommendation against the use of lopinavir-ritonavir in patients with covid-19, regardless of disease severity; (d) a strong recommendation for systemic corticosteroids in patients with severe and critical covid-19; (e) a conditional recommendation against systemic corticosteroids in patients with non-severe covid-19; and (f) a conditional recommendation against remdesivir in hospitalised patients with covid-19.
more
International Journal of Basic & Clinical Pharmacology 5(6):2290-2294
DOI: 10.18203/2319-2003.ijbcp20164081